Financial Supplement Q1 2025 Disclaimer This presentation contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which express management's current views concerning future business, events, trends, contingencies, financial performance, or financial condition, appear at various places in this communication and may use words like "aim," "anticipate," "assume," "believe," "continue," "could," "estimate," "expect," "forecast," "future," "goal, ...

Premier (PINC) Q3 2025 Earnings Call May 06, 2025 08:00 AM ET Speaker0 Good morning, and welcome to Premier's Fiscal twenty twenty five Third Quarter Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. I would now like to turn the call over to Ben Krasinski, Senior Director, Investor Relations. Please go ahead. Speaker1 Thank you, and welcome to Premier's fiscal year twenty twenty five third quarter conference call. Our speakers this morning are Mike Al ...

Fiscal 2025 Third-Quarter Earnings Conference Call May 6, 2025 © 2025. ALL RIGHTS RESERVED. | PREMIER INC. | 1 Forward-Looking Statements and Non-GAAP Financial Measures Key Points Forward-looking statements – Statements made in this presentation and the accompanying webcast that are not statements of historical or current facts, such as those related to our ability to advance our business strategies and improve healthcare, our ability to transition to partners or wind down the remaining operations of Conti ...

Group 1 - Sabra Healthcare reported revenue of $183.54 million for the quarter ended March 2025, reflecting a 10.1% increase year-over-year [1] - The company's EPS for the quarter was $0.37, significantly up from $0.11 in the same quarter last year [1] - The reported revenue exceeded the Zacks Consensus Estimate of $181.82 million, resulting in a surprise of +0.95% [1] Group 2 - The company delivered an EPS surprise of +2.78%, with the consensus EPS estimate being $0.36 [1] - Sabra's shares returned +0.8% over the past month, outperforming the Zacks S&P 500 composite's +0.4% change [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market [3] Group 3 - Interest and other income for the quarter was reported at $10.06 million, exceeding the average estimate of $9.43 million by analysts, representing a +12.5% change year-over-year [4] - Resident fees and services revenue was $77.45 million, slightly below the estimated $77.98 million, but still showing a +17.3% increase compared to the previous year [4] - Rental and related revenues were reported at $96.04 million, compared to the average estimate of $97.02 million, marking a +4.6% year-over-year change [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving HealthEquity, Inc and its officers or directors [1] Financial Performance - On March 18, 2025, HealthEquity reported its financial results for the fourth quarter and fiscal year ending January 31, 2025, with earnings per share that fell short of analyst expectations [3] - The company provided weak guidance for the fiscal year ending January 31, 2026, indicating potential challenges ahead [3] Stock Market Reaction - Following the announcement of disappointing earnings and guidance, HealthEquity's stock price dropped by $17.35 per share, or 17.07%, closing at $84.32 per share on March 19, 2025 [3] Cybersecurity Concerns - HealthEquity's management cited "excess service expense" due to increased cyber threats and fraud attacks, which have been attributed to sophisticated techniques employed by malicious actors [3]

Core Insights - 16 dividend growth companies announced increases in the second half of April, indicating a positive trend in dividend policies among these firms [1] - Predictions are made for an additional 7 companies expected to announce dividend increases in the first half of May, suggesting ongoing confidence in dividend growth [1] Group 1 - The article highlights the effectiveness of investing in dividend growth stocks and reinvesting dividends as a strategy for long-term wealth growth [1] - The author operates a blog, HarvestingDividends.com, which focuses on S&P Dividend Aristocrats and other dividend growth stocks, providing valuable insights for investors [1]

THREE MONTHS ENDED MARCH 31, 2025 Important Cautionary Notes All amounts in this Supplemental Information are in U.S. dollars unless otherwise specified. Unless otherwise indicated, the statistical and financial data in this document is presented as at March 31, 2025. CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS AND INFORMATION Note: This Supplemental Information contains "forward-looking information" within the meaning of Canadian provincial securities laws and "forward-looking statements" wit ...

MECHANICSBURG, Pa., May 1, 2025 /PRNewswire/ -- Select Medical Holdings Corporation ("Select Medical," "we," "us," or "our") (NYSE: SEM) today announced results for its first quarter ended March 31, 2025, and the declaration of a cash dividend.For the first quarter ended March 31, 2025, revenue increased 2.4% to $1,353.2 million, compared to $1,321.2 million for the same quarter, prior year. Income from continuing operations before other income and expense was $112.7 million for the first quarter ended Marc ...

Centene (CNC) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Since a ch ...

Wall Street analysts expect IQVIA Holdings (IQV) to post quarterly earnings of $2.63 per share in its upcoming report, which indicates a year-over-year increase of 3.5%. Revenues are expected to be $3.77 billion, up 0.9% from the year-ago quarter.Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timefr ...